Alkermes to Present Promising Narcolepsy Treatment Data at Annual Sleep Conference
Portfolio Pulse from Benzinga Newsdesk
Alkermes plc (NASDAQ: ALKS) will present promising clinical data for its narcolepsy treatment, ALKS 2680, at the SLEEP 2024 conference. The presentations will include data from a Phase 1b study and the design of a Phase 2 study, as well as qualitative patient interviews.
May 28, 2024 | 11:11 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alkermes will present promising data for its narcolepsy treatment, ALKS 2680, at the SLEEP 2024 conference. This includes Phase 1b study results and the design of a Phase 2 study, which could positively impact the stock price.
The presentation of promising clinical data and study designs for ALKS 2680 at a major conference could generate positive investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100